Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 5/20 | 0.33 |
| ▸ | ADH1C | P00326 | 4/20 | 0.33 |
| ▸ | ADH1B | P00325 | 2/20 | 0.31 |
| ▸ | ADH4 | P08319 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063218 | 0.93 | — | — | |
| SCHEMBL27901669 | 0.75 | ADH1A (0.36) | ADH1AADH1CADH1BADH4EPHX1 | |
| SCHEMBL3276795 | 0.75 | ADH1A (0.36) | ADH1AADH1CADH1BADH4EPHX1 | |
| Formamide SCHEMBL27969822 | 0.73 | EPHX1 (0.44) | ADH1AADH1CADH1BADH4EPHX1 | |
| SCHEMBL3271093 | 0.72 | ADH1A (0.32) | ADH1AADH1CADH1B | |
| SCHEMBL8520736 | 0.71 | ADH1A (0.33) | ADH1AADH1CADH1BADH4EPHX1 | |
| SCHEMBL3367234 | 0.71 | ADH1A (0.35) | ADH1AADH1C | |
| SCHEMBL23059323 | 0.71 | ALDH1A1 (0.50) | EPHX1SSTR4 | |
| SCHEMBL672134 | 0.71 | ALDH1A1 (0.33) | EPHX1SSTR4 | |
| SCHEMBL635368 | 0.71 | ALDH1A1 (0.33) | EPHX1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1006122-B1 | PHENETHYLAMINE DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2008-12-03 | — | — | EP | claimed |
| US-4016042-A | SYNTHETIC OLIGOPEPTIDE CONTAINING A CHROMOGENIC OR FLUORESCENT GROUP SPLIT OFF BY PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1977-04-05 | — | — | US | claimed |
| EP-2697249-B1 | COMPOUNDS BINDING TO THE BACTERIAL BETA RING | CENTRE NAT RECH SCIENT (FR) | 2018-10-10 | — | — | EP | disclosed |
| EP-2681209-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISORDERS | AQUILUS PHARMACEUTICALS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-9505743-B2 | Matrix metalloproteinase inhibitors and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS INC (US) | 2016-11-29 | — | — | US | disclosed |
| EP-2382206-B1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | AQUILUS PHARMACEUTICALS INC (US) | 2016-03-23 | — | — | EP | disclosed |
| US-20150274702-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | SUCHOLEIKI IRVING (US) | 2015-10-01 | — | — | US | disclosed |
| US-9133240-B2 | Compounds binding to the bacterial beta ring | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20140287989-A1 | Compounds Binding to the Bacterial Beta Ring | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2014-09-25 | — | — | US | disclosed |
| US-8765953-B2 | Compounds and methods for the treatment of pain and other diseases | AQUILUS PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2014062204-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | AQUILUS PHARMACEUTICALS, INC. (US) | 2014-04-24 | — | — | WO | disclosed |
| US-5599793-A | ANTICOAGULANTS | ELI LILLY AND COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0749316-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1996-12-27 | — | — | EP | disclosed |
| EP-0672658-A1 | Antithrombotic agents | ELI LILLY AND COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995023608-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995023609-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1995-09-08 | — | — | WO | disclosed |
| US-4568636-A | QUANTITATIVE ANALYSIS OF PROTEOLYTIC ENZYMES, FLUORESCENCE; COLORIMETRIC ANALYSIS | PENTAPHARM AG (CH) | 1986-02-04 | — | — | US | disclosed |
| US-4428874-A | QUANTITATIVE ANALYSIS OF PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1984-01-31 | — | — | US | disclosed |
| US-4358439-A | ANTIDIABETIC AGENT AND/OR GASTROINTESTINAL BLEEDING | CIBA-GEIGY CORPORATION (US) | 1982-11-09 | — | — | US | disclosed |
| US-4016042-A | SYNTHETIC OLIGOPEPTIDE CONTAINING A CHROMOGENIC OR FLUORESCENT GROUP SPLIT OFF BY PROTEOLYTIC ENZYMES | PENTAPHARM A.G. (CH) | 1977-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140287989-A1 | Compounds Binding to the Bacterial Beta Ring | PCNA, POLQ, DDB1 | ADH1A 4670/4885ADH1C 4334/4885ADH1B 4362/4885 |
| US-20150274702-A1 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR THE TREATMENT OF PAIN AND OTHER DISEASES | MMP13, MMP3, MMP9 | ADH1A 1516/4885ADH1C 2338/4885ADH1B 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.